Treatment of juvenile idiopathic arthritis: a revolution in care - Wikidata - wikimedia - TriplyDB

Treatment of juvenile idiopathic arthritis: a revolution in care

Treatment of juvenile idiopathic arthritis: a revolution in care

http://www.wikidata.org/entity/Q26849497

about

Contemporary management of TMJ involvement in JIA patients and its orofacial consequences Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.Effect of methotrexate on the mandibular development of arthritic rabbits Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.Treatment in juvenile rheumatoid arthritis and new treatment options.A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.APPROPRIATE DOSE ROUNDING OF CYTOKINE MODULATORS FOR PAEDIATRIC RHEUMATOLOGY INPATIENTS.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.Outcome of transition phase patients with juvenile idiopathic arthritis.Risk, Timing and Predictors of Disease Flare after Discontinuation of Anti-Tumor Necrosis Factor (TNF) Therapy in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis (JIA) in Clinical Inactive Disease.Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.Effect of methotrexate upon antigen-induced arthritis of the rabbit temporomandibular joint.Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what?Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases.Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.Innovations and Challenges by Applying Sublingual Laser Blood Irradiation in Juvenile Idiopathic Arthritis

P2860

Q26743409-362940B9-B46A-400C-BAFD-F1E31151E51E Q26766028-66217EFE-AAFF-4668-A7D4-07D38EF8F067 Q30235357-F69A6F03-9828-482E-BF2D-F727ADB3CE4E Q31034328-E565C419-47F1-4ED1-AE03-65AA3599E21A Q33435733-70D76285-D204-4532-8AB0-E61B9236B802 Q33795594-6FD0A4AA-D02F-457C-A23C-DF77D199BE09 Q36382268-9F99A621-4896-42D2-8CFB-38C448C9E991 Q37313894-4C07A54F-7511-4735-B3BF-9D1BE52218F3 Q38286209-7AEF42E9-36D7-4EE3-B291-9699CE8562D9 Q38421293-C09E7FB0-55EF-4486-8AB5-2DBACCD1C718 Q38528889-F56C45AD-4CEB-4720-A7FD-0708E7656325 Q38633441-47F8598A-CBEE-4919-847C-28BA47969379 Q38829898-7B280B62-A81C-41FF-855A-7354A819138E Q40179129-D6CA44F1-BDC3-4D05-BE4C-67410853D5BA Q43939571-0BA1147D-BEE2-47FD-9E8D-B64699EB54B0 Q47190952-95C70EA6-D97F-4F47-B5A0-5A848FAAAC16 Q52617055-610BC447-3CD0-4CBE-A98D-621FAE68DEFE Q52726577-54E23D25-2761-4184-B30C-E3A81C5DA4BF Q52873694-1BA1F75C-F147-4FB4-AB24-494641832E84 Q53071375-6FA5456D-B7AE-43F8-99FC-42FC516BDCA8 Q53279630-2253EDDB-F4D5-47F7-AC54-2A3292EF7334 Q55331950-CE05DB17-2528-44BD-A7A9-B6904EE619EA Q59044785-D9A7DFC4-6A42-470B-81E3-0634C6348EED

P2860

Treatment of juvenile idiopathic arthritis: a revolution in care

http://www.wikidata.org/entity/Q26849497

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Treatment of juvenile idiopathic arthritis: a revolution in care

@ast

Treatment of juvenile idiopathic arthritis: a revolution in care

@en

Treatment of juvenile idiopathic arthritis: a revolution in care

@nl

type

label

Treatment of juvenile idiopathic arthritis: a revolution in care

@ast

Treatment of juvenile idiopathic arthritis: a revolution in care

@en

Treatment of juvenile idiopathic arthritis: a revolution in care

@nl

prefLabel

Treatment of juvenile idiopathic arthritis: a revolution in care

@ast

Treatment of juvenile idiopathic arthritis: a revolution in care

@en

Treatment of juvenile idiopathic arthritis: a revolution in care

@nl

P1433

Q26849497-7C2DEAA4-359E-42EB-B98F-395D07118ED4

P1476

Q26849497-82585F58-42E3-495F-A278-DE0DC65DC379

P2093

Q26849497-6743C773-4238-4932-8271-D96D9BBBE476

P275

Q26849497-8FC6A58D-9CFD-4A96-A124-00A4CB9CF456

P2860

Q26849497-0084D768-8456-4AF2-9E4F-F7724923A0B9

Q26849497-011BFEBB-E150-48F3-AA7D-02A10CEB092A

Q26849497-038CA277-31F7-4FB8-A2FA-43C5BDED7CBD

Q26849497-03ABD404-3CDC-44DE-9779-7A2039B43DE2

Q26849497-05E3B39E-BEE5-4E71-942F-1A1079334E78

Q26849497-07C6F711-87F3-43A5-A00D-BC1652450614

Q26849497-08EC8B66-71F0-4C5F-9E07-FE1309A7AF44

Q26849497-0A89BB74-681A-4BA1-BBF2-D5EAE079BE0B

Q26849497-10EF44B5-B3CF-4EF1-A9A4-57CB1DF0D9B3

Q26849497-1437152B-2F98-45E8-8741-2B3D7DAC7396

P2888

Q26849497-AEB2BB9A-ABBF-4ECC-834B-92318387BEF1

P304

Q26849497-FAA8227A-C987-48F1-8874-2F052FA5D5A1

P31

Q26849497-D8104A0F-E075-468A-B1A6-8444486BEC52

P3181

Q26849497-E6C9710A-BA6B-4A33-B597-03128DC175C8

P356

Q26849497-2058B42B-59B5-4960-933B-115A47583ED1

P407

Q26849497-3A795BFD-F39A-48BA-A86D-1910FB0AD492

P478

Q26849497-2C7635E1-37B2-4E88-9530-2B3AD1B29A6D

P50

Q26849497-789BBEDA-872B-4D65-B51F-5E781B3710B5

P5008

Q26849497-1FB9EDED-E7B5-4480-9A57-3D7CC0BD035B

P577

Q26849497-9FC17BE3-958E-4073-90AA-D44FD8B206C3

P5875

Q26849497-4E529509-753E-4E70-ABAE-9663A475A9F8

P6179

Q26849497-429FF17F-8C1B-4286-9C72-ECCA5051D965

P698

Q26849497-248D2B8F-2FFE-46D4-947B-461527CA84D2

P921

Q26849497-3FC6249E-7B71-45D7-AC69-5E748F77E97C

Q26849497-562463D1-73E5-4165-B44C-40A0A51E1F97

P932

Q26849497-F54DD21C-C6DE-486C-8709-2459B8A18814

P3181

P356

1546-0096-12-13

P1433

Pediatric Rheumatology Online Journal

P1476

Treatment of juvenile idiopathic arthritis: a revolution in care

@en

P2093

Matthew L Stoll

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Rituximab for children with immune thrombocytopenia: a systematic review.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.

Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens.

P2888

1546-0096-12-13

P304

13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1087145

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1546-0096-12-13

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Randy Quentin Cron

P5008

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261999245

http://www.w3.org/2001/XMLSchema#string

P6179

1012904069

http://www.w3.org/2001/XMLSchema#string

P698

24782683

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

P932

4003520

http://www.w3.org/2001/XMLSchema#string